Document Detail


Prognostic value of plasma HER-2/neu in African American and Hispanic women with breast cancer.
MedLine Citation:
PMID:  10339653     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We examined the significance of plasma HER-2/neu as a clinical or biological marker for assessing the progression of breast cancer in African American and Hispanic women with similar socioeconomic status, similar health insurance, and similar access to health care delivery. Base line studies show the following: average age of our breast cancer patients was 48 for Hispanic and 53 for African American women. Most of our patients presented invasive ductal carcinoma, and there was no ethnic difference. A larger number of Hispanic women had stage III/IV disease at the time of diagnosis. There was no significant difference in the number of African American or Hispanic patients with ER positive or negative receptors. However, a larger number of Hispanic women had PR positive tumors, and a larger number of African American women had PR negative tumors. In general, there was no difference in the levels of HER-2/neu between the two ethnic groups. Patients with tumors >5 cm had elevated plasma HER-2/neu. However, there was no ethnic difference between tumor size and HER-2/neu levels. In addition, regional node status had no impact on plasma HER-2/neu. Patients with stage III/IV tumors had elevated plasma HER-2/neu. No ethnic difference was observed at either stage I/II or III/IV. ER positive or negative status had no significant impact on plasma HER-2/neu in either ethnic group. In contrast, PR positive patients showed elevated plasma HER-2/neu. Plasma HER-2/neu (>60 U/ml) was the strongest predictor of overall survival, visceral site metastasis, and local recurrence.
Authors:
Y Wu; H Khan; R Chillar; J V Vadgama
Related Documents :
16877193 - Toward a clinically useful method of predicting early breast-feeding attrition.
2788213 - How do women compare with internal medicine residents in breast lump detection? a study...
18591403 - Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the ...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  International journal of oncology     Volume:  14     ISSN:  1019-6439     ISO Abbreviation:  Int. J. Oncol.     Publication Date:  1999 Jun 
Date Detail:
Created Date:  1999-06-29     Completed Date:  1999-06-29     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  9306042     Medline TA:  Int J Oncol     Country:  GREECE    
Other Details:
Languages:  eng     Pagination:  1021-37     Citation Subset:  IM    
Affiliation:
Department of Medicine, Divisions of Laboratory Research and Development and Hematology/Oncology, Charles R. Drew University of Medicine and Science, UCLA School of Medicine, Los Angeles, CA 90059, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
African Continental Ancestry Group*
Aged
Aged, 80 and over
Breast Neoplasms / blood*,  ethnology*,  pathology
European Continental Ancestry Group*
Female
Hispanic Americans*
Humans
Lymph Nodes / pathology
Menopause
Middle Aged
Multivariate Analysis
Neoplasm Staging
Prognosis
Receptor, erbB-2 / blood*
Receptors, Estrogen / analysis
Receptors, Progesterone / analysis
Survival Analysis
Tumor Markers, Biological / blood*
Grant Support
ID/Acronym/Agency:
NCRR-RCMI-G12 RR 03026/RR/NCRR NIH HHS; P30 CA49095/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Receptors, Estrogen; 0/Receptors, Progesterone; 0/Tumor Markers, Biological; EC 2.7.10.1/Receptor, erbB-2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Lung cancer screening and the surgical oncologist: the controversy.
Next Document:  Non-metastatic Ewing's sarcoma: twenty years of experience suggests that surgery is a prime factor f...